Navigation Links
VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions

actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that the EvaMist NDA submission will be approved in a timely basis, or at all. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10- K for the year ended December 31, 2006 and periodic reports filed with the Securities and Exchange Commission.

Contact

VIVUS, Inc.
Timothy E. Morris, 650-934-5200
Chief Financial Officer
or
The Trout Group
Ian Clements (SF), 415-392-3385
Brian Korb (NYC), 646-378-2923


'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... WASHINGTON, Dec. 6, 2011  BodyMedia, the leading developer ... Qualcomm Life, a wholly owned subsidiary of Qualcomm ... BodyMedia FIT ™ LINK Armband ... BodyMedia Armband users to share wireless health data, ...
... 6, 2011  Echo Therapeutics, Inc. (Nasdaq: ECTE ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today announced a registered direct equity financing of approximately ... of one share of its common stock and a ...
Cached Medicine Technology:BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 2BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 3BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 4Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 2Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 3
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
(Date:7/9/2014)... that fecal transplantation is effective and safe for treating ... the result of a study led by Colleen Kelly, ... Medicine at The Women,s Medicine Collaborative. The study and ... print in the American Journal of Gastroenterology . ... , has increased to epidemic proportions over the past ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , , ... , , , , , ... binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... ... , , , , ... , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... Oct. 24 NetSuite Inc., a ... suites that provide,Accounting/ERP (Enterprise Resource Planning), ... for small and medium-sized,businesses and divisions ... NetSuite,partners and solution providers have introduced, ...
... THOR ), a world leader in products to treat,cardiovascular ... for the third quarter of fiscal 2007 on Thursday, ... call to discuss its financial,results and operating activities open ... (11:30 a.m., Eastern Daylight Time), Thursday,November 1, hosted by ...
... Cancer Prevention Expert and First Hispanic President ... Communications Expert Marion E. Morra to,Lead Volunteer Board ... American Cancer,Society, the nation,s largest voluntary health organization, ... Board of Directors during its,annual meeting held this ...
... 25 3M and,Zargis Medical Corp., a spin-off ... a majority-owned subsidiary of Speedus Corp. (Nasdaq: ... involving Zargis,heart sound analysis software and 3M Littmann,s ... support 3M in its efforts to develop a,next-generation ...
... (E) Executive Director, ... American Public Health Association, WASHINGTON, Oct. 25 ... House of Representatives,today to support legislation to reauthorize the Children,s ... points of,opposition. They,ve come up with a plan that even ...
... October 25, 2007 - Postmenopausal women are at ... the chronic health conditions associated with obesity become ... of Obstetric, Gynecologic, & Neonatal Nursing reviews the ... that are relevant to postmenopausal women. The article ...
Cached Medicine News:Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 2Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 3Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 5Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 6Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 7Health News:Thoratec Schedules Third Quarter Conference Call, Webcast 2Health News:New Volunteers Selected to Lead American Cancer Society 2Health News:New Volunteers Selected to Lead American Cancer Society 3Health News:New Volunteers Selected to Lead American Cancer Society 4Health News:New Volunteers Selected to Lead American Cancer Society 5Health News:New Volunteers Selected to Lead American Cancer Society 6Health News:3M and Zargis Announce Global Marketing Alliance 2Health News:3M and Zargis Announce Global Marketing Alliance 3Health News:3M and Zargis Announce Global Marketing Alliance 4
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: